<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-12-15">15 December 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Helen</forename><surname>Mann</surname></persName>
							<email>helen.mann@astrazeneca.com</email>
							<affiliation key="aff0">
								<orgName type="institution">AstraZeneca</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">•</forename><forename type="middle">Frank</forename><surname>Andersohn</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">Frank Andersohn Consulting and Research Services</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Institute for Social Medicine, Epidemiology and Health Economics</orgName>
								<orgName type="institution">Charite ´University Medicine</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carolyn</forename><surname>Bodnar</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">AstraZeneca</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tetsuya</forename><surname>Mitsudomi</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Division of Thoracic Surgery</orgName>
								<orgName type="department" key="dep2">Department of Surgery</orgName>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution">Kindai University</orgName>
								<address>
									<settlement>Osaka-Sayama</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tony</forename><forename type="middle">S K</forename><surname>Mok</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Clinical Oncology</orgName>
								<orgName type="institution" key="instit1">State Key Laboratory of South China</orgName>
								<orgName type="institution" key="instit2">Hong Kong Cancer Institute</orgName>
								<orgName type="institution" key="instit3">Prince of Wales Hospital</orgName>
								<orgName type="institution" key="instit4">The Chinese University of Hong Kong</orgName>
								<address>
									<settlement>Sha Tin, Hong Kong</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">•</forename><surname>James</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Chih-Hsin</forename><surname>Yang</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">National Taiwan University Hospital</orgName>
								<address>
									<addrLine>Taipei 100</addrLine>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Eisai Europe Ltd</orgName>
								<address>
									<settlement>Hatfield</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christopher</forename><surname>Hoyle</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">AstraZeneca</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-12-15">15 December 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">F56A77A75F384E49338CF557A0C875E9</idno>
					<idno type="DOI">10.1007/s40261-017-0611-3</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:46+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background and objective An adjusted indirect comparison was conducted to assess efficacy outcomes, particularly overall survival (OS), of osimertinib versus platinumbased doublet chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) T790M mutation-positive non-small-cell lung cancer (NSCLC) who had progressed following an EGFR tyrosine kinase inhibitor (TKI).</s><s>Analysis of treatment effect from two separate trials had the potential to more accurately estimate the magnitude of OS benefit due to absence of confounding due to treatment switching from the control arm to the osimertinib arm of the ongoing randomized control trial, AURA3.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Methods Two non-randomized individual datasets were compared: pooled patients from the AURA extension and AURA2 trials (osimertinib 80 mg, n = 405, with a confirmed T790M mutation using tissue samples), and patients from the control arm of the IMPRESS study (platinumbased doublet chemotherapy, n = 61, with a confirmed T790M mutation using plasma circulating tumour DNA <ref type="bibr">[ctDNA]</ref>).</s><s>A propensity score-based approach was used to account for differences in baseline demographics and disease characteristics.</s><s>Results After adjustment for baseline differences between the two groups, osimertinib demonstrated a statistically significant improvement in progression-free survival (PFS) versus platinum-based doublet chemotherapy (hazard ratio [HR] = 0.278, 95% confidence interval [CI] 0.188-0.409,</s><s>p\0.0001; median PFS 10.9 vs. 5.3 months).</s><s>Improvements were also observed for objective response rate (ORR) and disease control rate (DCR) (ORR: 64.3 vs. 33.3%;</s><s>odds ratio [OR] = 5.31, 95% CI 2.47-11.40,</s><s>p\0.001;</s><s>DCR: 92.1 vs. 75.0%;</s><s>OR = 4.72, 95% CI 1.92-11.58,</s><s>p\0.001).</s><s>Similar results were obtained for patients who received osimertinib as second-line treatment only.</s><s>A statistically significant improvement in OS was observed for the osimertinib group (HR = 0.412, 95% CI 0.273-0.622,</s><s>p\0.0001).</s><s>Median OS for osimertinib was not reached.</s><s>Conclusions In this indirect comparison, osimertinib showed a statistically significant improvement in efficacy outcomes versus platinum-based doublet chemotherapy in patients with EGFRm T790M NSCLC who had progressed after EGFR-TKI therapy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">Introduction</head><p><s>The majority of epidermal growth factor receptor-mutated (EGFRm) patients with locally advanced or metastatic nonsmall-cell lung cancer (NSCLC) treated with an EGFR tyrosine kinase inhibitor (TKI) ultimately develop acquired resistance and generally progress within 1 year <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref>.</s><s>The median survival of patients after the emergence of acquired resistance is generally less than 2 years <ref type="bibr" target="#b3">[4]</ref>.</s></p><p><s>One of the main pathways for development of drug resistance to first-and second-generation EGFR-TKIs is the emergence of a second point mutation resulting in substitution of threonine with methionine at amino acid position 790 at exon 20 (T790M) <ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref>.</s><s>The T790M point mutation is found in approximately 50-60% of all patients at the time of acquired resistance to EGFR-TKI therapy <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b7">8]</ref>.</s><s>Prior to development of osimertinib, there were no approved therapies that specifically targeted the acquired T790M mutation.</s><s>Instead, therapeutic options for patients progressing with EGFR T790M mutation-positive NSCLC were limited to platinum-based doublet chemotherapy, salvage chemotherapy (approved for use after failure of platinum-based doublet chemotherapy), investigational agents and combinations, EGFR-TKI re-challenge, and best supportive care-all of which are associated with limited efficacy <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref>.</s></p><p><s>Osimertinib is an oral, potent, selective, irreversible EGFR-TKI, active against both EGFRm (TKI sensitivityconferring mutations) and T790M mutation-positive (TKI resistance-conferring mutation) forms of EGFR <ref type="bibr" target="#b19">[19]</ref>.</s><s>Early approvals of osimertinib (80 mg once daily) in North America, Europe and Asia have been based on evidence from two phase II single-arm trials, the extension phase of the AURA trial (NCT01802632) and AURA2 (NCT02094261) <ref type="bibr" target="#b19">[19]</ref><ref type="bibr" target="#b20">[20]</ref><ref type="bibr" target="#b21">[21]</ref><ref type="bibr" target="#b22">[22]</ref>.</s><s>More recently, randomized data from the confirmatory AURA3 study (NCT02151981) have become available and demonstrated a significant improvement in progression-free survival (PFS) for osimertinib compared with platinum-based therapy plus pemetrexed in patients with EGFR T790M mutation-positive NSCLC <ref type="bibr" target="#b23">[23,</ref><ref type="bibr" target="#b24">24]</ref>.</s></p><p><s>In addition to randomized efficacy data, adjusted indirect comparisons using patient-level data can be used to determine valid estimates of treatment effect.</s><s>These analyses have the utility to provide additional evidence for reimbursement assessments to support launches based only on single-arm trials; to provide validation and supportive evidence for comparative endpoints in preparation for when randomized controlled trials do become available; and to support those studies where long-term comparative efficacy data may never be available due to the ability of patients to switch to the trial treatment (a growing trend in oncology).</s><s>This is applicable to osimertinib given that switching treatment is allowed in the AURA3 trial; therefore, the overall survival (OS) hazard ratio (HR) from an adjusted indirect comparison would be important.</s></p><p><s>To perform an adjusted indirect comparison, we used the control arm (platinum-based doublet chemotherapy and placebo) of the IMPRESS study (NCT01544179), which included a subgroup of patients with the T790M mutation (as identified by plasma-circulating tumour DNA [ctDNA]) and disease progression following response to EGFR-TKI <ref type="bibr" target="#b25">[25]</ref>.</s><s>These patients have similar demographic and disease characteristics to those in the AURA extension and AURA2 trials of osimertinib and represent a valid comparator to demonstrate differences in efficacy outcomes for osimertinib versus platinum-based doublet chemotherapy.</s><s>Using these populations, we report on a non-randomized, adjusted comparison of efficacy outcomes of osimertinib versus platinum-based doublet chemotherapy for treatment of patients with EGFR T790M mutation-positive advanced NSCLC who have progressed following EGFR-TKI.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">Study Designs</head><p><s>The efficacy of osimertinib relative to platinum-based doublet chemotherapy was assessed using an adjusted indirect comparison of two datasets comprising patients with a confirmed T790M mutation by tissue from the AURA trials and patients with a confirmed T790M mutation by plasma from the placebo-chemotherapy arm of the phase III randomized IMPRESS trial.</s><s>The study designs of the AURA and IMPRESS trials have been previously reported and are summarized in Table 1 <ref type="bibr" target="#b19">[19,</ref><ref type="bibr" target="#b25">25]</ref>.</s><s>AURA2 was almost identical in design to the AURA extension trial The mean time difference between most recent progression to start of treatment for pooled data of AURA extension and AURA2 was 78.20 days and was 17.05 days for the T790M mutation-positive subgroup of the chemotherapy arm of IMPRESS (Supplementary Table <ref type="table" target="#tab_0">1</ref>)</s></p><formula xml:id="formula_0">d</formula><p><s>Baseline assessments had to be performed no more than 4 weeks before the start of treatment, and ideally as close as possible to the start of study treatment.</s><s>Follow-up assessments were performed every 6 weeks after randomization (within a window of ± 7 days of the scheduled date) until objective disease progression as defined by RECIST.</s><s>At screening, eligibility was decided as quickly as possible to shorten the time from documented radiological progression to start of pemetrexed in combination with cisplatin and randomized study treatment.</s><s>From Day -28 to Day 0 was preferred.</s><s>Following progression, but before randomization, continuation of gefitinib was encouraged.</s><s>However, if a patient stopped taking gefitinib treatment, the maximum allowed time off treatment prior to randomization was 4 weeks.</s><s>All other screening assessments had to be completed within the specified 28 days</s></p><p><s>Adjusted Indirect Comparison of Osimertinib to Platinum-Based Chemotherapy with the studies prospectively planned to provide replication of data (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Given the similar trial designs, patients from the AURA extension and AURA2 studies were pooled to increase the precision of the estimate of the primary efficacy endpoint.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">Population</head><p><s>Summaries and analyses of endpoints are based on the T790M mutation-positive patients from the pooled AURA extension and AURA2 trials and the control arm of the IMPRESS trial.</s><s>In AURA extension and AURA2, T790M mutation testing was performed centrally on tumour tissue using the cobas Ò EGFR mutation test (Roche Molecular Systems Inc).</s><s>Tumour biopsies were taken after confirmation of disease progression on the most recent treatment regimen <ref type="bibr" target="#b19">[19]</ref>.</s><s>In IMPRESS, biomarker research was performed for EGFR mutations, including T790M mutation status, using ctDNA <ref type="bibr" target="#b26">[26]</ref>.</s><s>For patients in the pooled AURA population, 405/411 treated with osimertinib 80 mg had a confirmed T790M mutation and were included in the analysis (Table <ref type="table" target="#tab_0">1</ref>).</s><s>For patients in the pooled AURA population who were in the second-line treatment setting, 127/129 had a confirmed T790M mutation.</s><s>For patients in the chemotherapy arm of the IMPRESS study, 61/132 patients had a confirmed T790M mutation by ctDNA.</s></p><p><s>As discussed in the statistical methods below, prior to analysis of endpoints, differences between baseline (i.e.</s><s>pre-randomization), demographic and disease characteristics were accounted for by cohort balancing to provide the dataset for analysis of efficacy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3">Efficacy Endpoints</head><p><s>Primary analysis endpoints were PFS, objective response rate (ORR, defined as the number [%] of patients with measurable disease with at least one confirmed visit response of complete response [CR] or partial response [PR]), disease control rate (DCR, defined as the percentage of patients who have a best objective response of CR, PR or stable disease) and OS.</s><s>PFS, DCR and ORR are reported based on independent central review (ICR) of radiological data.</s><s>Analyses were also performed on PFS, ORR, DCR and OS for second-line patients only.</s><s>PFS was defined as the time from first dose in the AURA extension and AURA2 studies and time from randomization in the IMPRESS study to the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from randomized therapy or received another anti-cancer therapy prior to progression.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4">Statistical Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.1">Cohort Balancing</head><p><s>Differences between baseline (i.e.</s><s>pre-randomization), demographic and disease characteristics in the AURA and IMPRESS trials (see Supplementary Table <ref type="table" target="#tab_0">1</ref>) were accounted for by a three-step process of adjustment, referred to as cohort balancing (Fig. <ref type="figure">1</ref>) <ref type="bibr" target="#b27">[27]</ref>.</s><s>The resulting adjustment is assumed to be a proxy for randomization and enables a robust comparison between osimertinib and platinum-based doublet chemotherapy using individual patient data from the AURA and IMPRESS studies, respectively.</s></p><p><s>The first step compared baseline demographic and disease characteristics with inclusion of those variables with a p value\0.2 into estimation of propensity scores (PS) (Fig. <ref type="figure">1</ref>).</s><s>The second step involved estimation of PS.</s><s>The PS for an individual is the probability of being treated with osimertinib/platinum-based doublet chemotherapy conditional on the individual's baseline variables.</s><s>PS for each Fig. <ref type="figure">1</ref> Process for cohort balancing of the osimertinib and platinumbased doublet chemotherapy groups patient was estimated using logistic regression modelling (Fig. <ref type="figure">1</ref>).</s><s>The overlap between cohorts on estimated PS was assessed and only patients within the PS distributions of both treatment groups were included in the final analyses; a process termed 'trimming' <ref type="bibr" target="#b28">[28]</ref>.</s><s>The overlap was identified as all values between the minimum of the PS in patients treated with osimertinib and the maximum of the PS in patients treated with platinum-based doublet chemotherapy.</s><s>In the final step, PS was incorporated as a covariate for analysis of the treatment comparison of osimertinib versus platinum-based doublet chemotherapy for each endpoint to adjust for remaining differences between groups (Fig. <ref type="figure">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.2">Analysis of Treatment Effects</head><p><s>All analyses were performed using the dataset produced by cohort balancing as described above.</s><s>Summaries and analyses for ORR and DCR were based on the evaluablefor-response subset, defined as all patients who received at least one dose of treatment and had measurable disease at baseline according to the ICR or baseline imaging data.</s><s>Analysis of ORR and DCR for osimertinib relative to platinum-based doublet chemotherapy was performed using a logistic regression model containing treatment as a factor and the propensity score as a covariate.</s><s>PFS and OS    The effect of trimming (i.e.</s><s>removal of patients for which the value of the calculated PS was not within the overlapping region between the two study groups) was evaluated for the endpoints PFS, ORR, DCR and OS.</s><s>Sensitivity analyses were performed on the T790M?adj untrimmed set to evaluate the effect of removing subjects to produce the trimmed dataset.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">Results</head><p><s>The results used to identify the variables for inclusion in the PS model are provided in Table <ref type="table" target="#tab_1">2</ref>.</s><s>A full list of variables assessed for inclusion is provided in Supplementary Table <ref type="table" target="#tab_0">1</ref>.</s><s>Twenty-two initial variables were identified, including a larger mean tumour size in the AURA trials (Supplementary Table <ref type="table" target="#tab_0">1</ref>).</s><s>Variables with p\0.2 were included in the PS model.</s><s>Following cohort balancing, 288/405 patients were retained in the osimertinib group and 53/61 patients were retained in the platinum-based doublet chemotherapy group; of these, 92 and 53 patients, respectively, received osimertinib or platinum-based doublet chemotherapy as second-line therapy.</s><s>Baseline demographics and disease characteristics for these populations are shown in Table <ref type="table" target="#tab_2">3</ref>.</s></p><p><s>Patients in the osimertinib group were older relative to the platinum-based doublet chemotherapy group (mean age 60.6 vs. 56.7 years, p = 0.0156) (Table <ref type="table" target="#tab_2">3</ref>).</s><s>The mean time from recent progression to start of treatment was longer for the osimertinib group compared with the platinum-based doublet chemotherapy group (74.1 vs. 16.9 days, p\0.001), reflecting the difference in trial design whereby patients in the IMPRESS study were randomized within 4 weeks of disease progression following first-line treatment.</s><s>Significantly more patients received previous platinum-based doublet chemotherapy and previous platinumbased doublet chemotherapy plus bevacizumab therapy in the osimertinib group compared with the platinum-based doublet chemotherapy group due to the differences in design of the IMPRESS and AURA trials.</s><s>Similar differences in age and mean time from recent progression to start of treatment were observed for patients who received osimertinib or platinum-based doublet chemotherapy as second-line treatment (Table <ref type="table" target="#tab_2">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">Progression-Free Survival</head><p><s>Median PFS of osimertinib and platinum-based doublet chemotherapy was 10.9 and 5.3 months, respectively (HR 0.278, 95% CI 0.188-0.409,</s><s>p\0.0001) (Fig. <ref type="figure">2a</ref>).</s></p><p><s>A statistically significant improvement in median PFS was also observed for the osimertinib group compared with the platinum-based doublet chemotherapy group for the subset of patients treated with osimertinib (n = 92) or platinum-based doublet chemotherapy (n = 53) as secondline treatment (HR 0.251, 95% CI 0.155-0.405,</s><s>p\0.0001; median 9.7 vs. 5.3 months) (Fig. <ref type="figure">2b</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">PFS Sensitivity Analysis: Untrimmed Data Set</head><p><s>Use of the untrimmed data set and the PS as a covariate for all patients with T790M?</s><s>status demonstrated a statistically significant improvement for the osimertinib group relative to the platinum-based doublet chemotherapy group of 10.9 months and 5.3 months, respectively (HR 0.283, 95% CI 0.194-0.412,</s><s>p\0.0001).</s><s>Similarly, using the untrimmed dataset and PS as a covariate for T790M?</s><s>patients receiving second-line treatment demonstrated a statistically significant improvement for the osimertinib group relative to the platinum-based doublet chemotherapy group of 9.8 months and 5.3 months respectively (HR 0.250, 95% CI 0.157-0.397,</s><s>p\0.0001).</s><s>These results are consistent with those produced using the trimmed data set.</s><s>The improvement for osimertinib was similar to the unadjusted comparison with the platinum-based doublet chemotherapy group (HR 0.28, 95% CI 0.19-0.41,</s><s>p\0.001).</s><s>For patients treated with osimertinib or platinum-based doublet chemotherapy as second-line treatment (n = 89 osimertinib; n = 48 platinum-based doublet chemotherapy), a statistically significant improvement in ORR and DCR was also observed for the osimertinib group compared with the platinum-based doublet chemotherapy group (ORR: 67.4 vs. 33.3%,</s><s>OR 5.63, 95% CI 2.32-13.67,</s><s>p\0.001;</s><s>DCR: 93.3 vs. 75.0%,</s><s>OR 5.73, 95% CI 1.84-17.88,</s><s>p = 0.003).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3">Objective Response</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4">Overall Survival</head><p><s>At the data cut-off for OS (pooled AURA dataset: 1 November 2016; platinum-based doublet chemotherapy group: 16 November 2015), median OS time for the A B Fig. <ref type="figure">3</ref> Kaplan-Meier plot of overall survival by independent central review a for all patients following cohort balancing: n = 288 receiving osimertinib; n = 53 receiving platinumbased doublet chemotherapy, b for subset of patients receiving osimertinib (n = 92) or platinum-based doublet chemotherapy (n = 53) as a second-line treatment osimertinib group was not calculable for the pooled AURA dataset and the median OS time for the platinum-based doublet chemotherapy group was 14.1 months.</s><s>The HR for OS for osimertinib relative to platinum-based doublet chemotherapy was 0.412 (95% CI 0.273-0.622,</s><s>p = 0.0001) (Fig. <ref type="figure">3a</ref>).</s></p><p><s>For patients who received osimertinib or platinum-based doublet chemotherapy as second-line treatment, at the data cut-off for OS, median OS time for the osimertinib group was 26.5 months and the median OS time for the platinumbased doublet chemotherapy group was 14.1 months.</s><s>The HR for OS for osimertinib relative to platinum-based doublet chemotherapy was 0.459 (95% CI 0.279-0.754,</s><s>p = 0.0025) (Fig. <ref type="figure">3b</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5">Overall Survival: Censored at Longest Followup for Osimertinib</head><p><s>To account for potential differences in follow-up time between the AURA extension/AURA2 and IMPRESS studies, a sensitivity analysis was conducted, in which patients in the IMPRESS study were censored at the point of longest follow-up in the AURA extension/AURA2 studies.</s><s>The median OS time for the osimertinib group was not calculable, which was consistent with the pooled analysis for AURA extension and AURA2 data.</s><s>Median OS time for the platinum-based doublet chemotherapy group was 14.1 months.</s><s>The HR for OS for osimertinib relative to platinum-based doublet chemotherapy was 0.413 (95% CI 0.273-0.623,</s><s>p = 0.0001) (Fig. <ref type="figure" target="#fig_1">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4">Discussion</head><p><s>Prior to the approval of osimertinib, approaches to address patients with EGFR T790M mutation-positive NSCLC, the most common cause of acquired drug resistance in EGFRm NSCLC, have been limited by a lack of efficacy and doselimiting toxicity <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b29">[29]</ref><ref type="bibr" target="#b30">[30]</ref><ref type="bibr" target="#b31">[31]</ref><ref type="bibr" target="#b32">[32]</ref><ref type="bibr" target="#b33">[33]</ref><ref type="bibr" target="#b34">[34]</ref><ref type="bibr" target="#b35">[35]</ref>.</s><s>Osimertinib recently received regulatory approvals in North America, Europe and Asia as the first indicated treatment for patients with metastatic EGFR T790M mutation-positive NSCLC <ref type="bibr" target="#b20">[20,</ref><ref type="bibr" target="#b21">21,</ref><ref type="bibr" target="#b36">36,</ref><ref type="bibr" target="#b37">37]</ref>.</s><s>Approval was based on evidence from the AURA extension and AURA2 phase II single-arm trials <ref type="bibr" target="#b19">[19]</ref>.</s><s>Prior to publication of randomized, comparative control data for osimertinib, across different endpoints, from the AURA3 trial, we performed an adjusted indirect comparison of osimertinib with platinum-based doublet chemotherapy.</s></p><p><s>The approach allows the comparison of treatment results with platinum-based doublet chemotherapy when only single-arm trial results are available, thereby offering a bridging methodology until phase III confirmatory trial data are available.</s><s>The approach continues to have utility when phase III trial data are available, as patients switching to trial treatment is becoming more frequent in randomized oncology trials, resulting in confounding of post-switch endpoints, such as OS.</s><s>Confounding makes determination of OS impact more challenging.</s><s>It is anticipated that AURA3 may not provide a true measure of OS benefit due to a high proportion (60%) of patients switching to osimertinib from the comparator treatment <ref type="bibr" target="#b24">[24]</ref>.</s><s>Therefore, data from these types of indirect comparison studies may provide the best available survival estimate.</s><s>Additionally, they may help inform appropriate statistical methods that can adjust for the impact of treatment switching.</s></p><p><s>Our study used PS analyses to adjust for imbalances in demographics and clinical characteristics.</s><s>It should be noted that although PS can balance observed baseline covariates between exposure groups, it cannot balance unmeasured characteristics and confounders.</s><s>Hence, as with all observational studies, and unlike blinded randomized controlled trials, PS analyses have the limitation that unobserved differences between the two groups will more likely confound analysis of efficacy.</s><s>However, the large effect size observed in our study suggests that a comparative benefit would remain despite the possibility of unmeasured confounders.</s><s>In addition, approaches using the PS do not overcome initial selection bias.</s><s>For example, time from recent (radiological) disease progression to start of treatment differed between the IMPRESS and AURA trials.</s><s>Whereas all patients in the platinum-based doublet chemotherapy group started treatment within 29 days of previous documented disease progression, only 25/405 patients in the osimertinib group started treatment within this period.</s><s>This variable was excluded from the list of candidate variables as adjustment was not feasible.</s><s>However, non-inclusion of this variable seems acceptable as the delayed start of treatment for osimertinib is most likely a disadvantage for the osimertinib group (i.e.</s><s>results from analysis of efficacy would be a conservative estimate of the benefit of osimertinib).</s></p><p><s>Sensitivity analyses using the untrimmed dataset and PS as a covariate for patients with T790M?</s><s>status produced results consistent with those produced using both the trimmed data set and the unadjusted platinum-based doublet chemotherapy group.</s></p><p><s>T790M mutation was determined using different methodologies in the two studies: tissue biopsy in AURA and plasma ctDNA in IMPRESS.</s><s>Tissue biopsy was not available for IMPRESS for comparison.</s><s>Of the different testing methodologies, tissue biopsy is regarded as the gold standard.</s><s>In a retrospective assessment of plasma genotyping in patients with advanced NSCLC who were treated with osimertinib, similar efficacy outcomes were reported in patients with T790M-positive plasma samples (ORR, 63%; median PFS, 9.7 months) compared with patients with T790M-positive tumour samples (ORR, 62%; median PFS, 9.7 months) <ref type="bibr" target="#b38">[38]</ref>.</s><s>These data suggest that the use of plasma versus tissue testing is unlikely to impact on the efficacy outcomes with platinum-based doublet chemotherapy, which is an untargeted treatment, and further suggest that a positive plasma test is a reliable way to select patients for osimertinib treatment <ref type="bibr" target="#b38">[38]</ref>.</s><s>In addition, there is greater than 90% concordance across two platforms (cobas Ò and BEAMing) used for T790M mutation detection <ref type="bibr" target="#b39">[39]</ref>.</s></p><p><s>Taking the limitations highlighted above into consideration, the findings of this indirect comparison demonstrated a statistically significant and clinically meaningful improvement in PFS, ORR and DCR for osimertinib relative to platinum-based doublet chemotherapy.</s><s>The median PFS for osimertinib and for platinum-based doublet chemotherapy reported in our study (10.9 and 5.3 months, respectively) were consistent with previously reported PFS for osimertinib-treated EGFR T790M mutation-positive patients in the AURA extension trial (9.6 months) <ref type="bibr" target="#b19">[19]</ref> and the control arm of the IMPRESS trial (5.4 months) <ref type="bibr" target="#b25">[25]</ref>.</s></p><p><s>This indirect comparison reported a statistically significant OS benefit in favour of the osimertinib group.</s><s>However, as data for OS were immature for the osimertinib group, median OS for osimertinib had not been reached at and further updates may be anticipated.</s><s>Randomized data from the phase III AURA3 trial, which evaluated osimertinib compared with platinum-based therapy plus pemetrexed in patients with EGFR T790M mutation-positive NSCLC, have now been published <ref type="bibr" target="#b23">[23,</ref><ref type="bibr" target="#b24">24]</ref>.</s><s>Consistent with the findings from our indirect comparison, in AURA3, osimertinib treatment led to significant improvements in PFS (HR 0.30, 95% CI 0.23-0.41,</s><s>p\0.001; median PFS 10.1 vs. 4.4 months) and ORR (71 vs. 31%; OR 5.39, 95% CI 3.47-8.48,</s><s>p\0.001) when compared with platinum-based therapy plus pemetrexed (Table <ref type="table" target="#tab_6">4</ref>) <ref type="bibr" target="#b23">[23,</ref><ref type="bibr" target="#b24">24]</ref>.</s></p><p><s>The absence of adjustment for differences due to confounding of unmeasured patient characteristics is a limitation of any indirect comparison.</s><s>However, the acceptable level of consistency of the results of the indirect comparison and AURA3 provide evidence that the indirect approach is valid, particularly for estimation of OS where analysis of the RCT is heavily confounded due to treatment switching from the chemotherapy arm to osimertinib <ref type="bibr" target="#b24">[24]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5">Conclusions</head><p><s>In summary, our findings suggest that osimertinib may be a more effective treatment than platinum-based doublet chemotherapy in patients with metastatic EGFRm T790M mutation-positive NSCLC who have progressed after EGFR-TKI, improving ORR, DCR, and PFS consistent with phase III data from AURA3 <ref type="bibr" target="#b23">[23,</ref><ref type="bibr" target="#b24">24]</ref>.</s><s>In addition, the analysis of OS bridges the available evidence for the improved survival with osimertinib from AURA3, which is heavily confounded due to treatment switching.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 4</head><label>4</label><figDesc><div><p><s>Fig. 4 Kaplan-Meier plot of overall survival censored at point on longest follow-up for osimertinib (T790M?adj set) for all patients following cohort balancing: n = 288 receiving osimertinib; n = 53 receiving platinum-based doublet chemotherapy</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s><ref type="bibr" target="#b19">[19,</ref><ref type="bibr" target="#b25">25]</ref> of study designs of the AURA extension, AURA2 and IMPRESS trials[19,25]</s></p></div></figDesc><table><row><cell>Characteristics</cell><cell>AURA extension</cell><cell>AURA2</cell><cell>IMPRESS</cell></row><row><cell>Clinical trial</cell><cell>NCT01802632</cell><cell>NCT02094261</cell><cell>NCT01544179</cell></row><row><cell>identifier</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Study type</cell><cell>Phase II, open-label, single-arm,</cell><cell>Phase II, open-label, single-arm</cell><cell>Phase III randomized, double-blind,</cell></row><row><cell></cell><cell>multicentre</cell><cell></cell><cell>placebo-controlled, parallel, multicentre</cell></row><row><cell></cell><cell></cell><cell></cell><cell>study</cell></row><row><cell>T790M central</cell><cell>Performed prospectively; central</cell><cell>Performed prospectively; central result</cell><cell>Performed retrospectively; central result</cell></row><row><cell>testing</cell><cell>result (cobas Ò EGFR mutation test),</cell><cell>(cobas Ò EGFR mutation test),</cell><cell>(BEAMing plasma assay) as exploratory</cell></row><row><cell></cell><cell>mandatory to determine eligibility</cell><cell>mandatory to determine eligibility</cell><cell>objective</cell></row><row><cell>Primary efficacy</cell><cell>ORR based on RECIST v1.1 assessed</cell><cell>ORR based on RECIST v1.1 assessed</cell><cell>PFS for continuing gefitinib plus</cell></row><row><cell>objective</cell><cell>by BICR</cell><cell>by BICR</cell><cell>platinum-based doublet chemotherapy</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs. platinum-based doublet</cell></row><row><cell></cell><cell></cell><cell></cell><cell>chemotherapy alone</cell></row><row><cell>Secondary</cell><cell>DCR, DoR, time to first</cell><cell>DCR, DoR, time to first documentation</cell><cell>OS, ORR and DCR for continuing</cell></row><row><cell>efficacy</cell><cell>documentation of objective</cell><cell>of objective response, best change</cell><cell>gefitinib plus platinum-based doublet</cell></row><row><cell>objectives</cell><cell>response, best change from baseline</cell><cell>from baseline in size of TL, PFS and</cell><cell>chemotherapy vs. platinum-based</cell></row><row><cell></cell><cell>in size of TL, PFS and OS</cell><cell>OS</cell><cell>doublet chemotherapy alone</cell></row><row><cell>Dosing and</cell><cell>Osimertinib 80 mg tablet taken once</cell><cell>Osimertinib 80 mg tablet taken once</cell><cell>Control arm received standard pemetrexed</cell></row><row><cell>patient cohorts</cell><cell>daily</cell><cell>daily</cell><cell>plus cisplastin chemotherapy (maximum</cell></row><row><cell></cell><cell>Second-line patients (pre-treated with one EGFR-TKI and no other</cell><cell>Second-line patients (pre-treated with one EGFR-TKI and no other treatment</cell><cell>six cycles, intravenously on Day 1 of each cycle) a</cell></row><row><cell></cell><cell>treatment regimens), n = 61</cell><cell>regimen), n = 68</cell><cell></cell></row><row><cell></cell><cell>C Third-line patients (pre-treated</cell><cell>C Third-line patients (pre-treated with</cell><cell></cell></row><row><cell></cell><cell>with at least one EGFR-TKI and</cell><cell>at least one EGFR-TKI and one</cell><cell></cell></row><row><cell></cell><cell>one other prior line of therapy),</cell><cell>platinum-based doublet chemotherapy</cell><cell></cell></row><row><cell></cell><cell>n = 140</cell><cell>regimen), n = 142</cell><cell></cell></row><row><cell>Study period</cell><cell>First dose of first patient: 14 May</cell><cell>First dose of first patient: 13 June 2014;</cell><cell>First patient enrolled: 29 March 2012; last</cell></row><row><cell></cell><cell>2014; first dose of last patient: 21</cell><cell>first dose of last patient: 27 October</cell><cell>patient enrolled: 9 December 2013</cell></row><row><cell></cell><cell>October 2014</cell><cell>2014</cell><cell></cell></row><row><cell>Data cut-off</cell><cell>1 November 2016 b</cell><cell>1 November 2016 b</cell><cell>16 November 2015</cell></row><row><cell>Assessment of</cell><cell>Screening, -28 days to date of first</cell><cell>Screening, -28 days to date of first</cell><cell>Screening, -4 weeks to date of</cell></row><row><cell>tumour</cell><cell>dose (day 0) and every 6 weeks</cell><cell>dose (day 0) and every 6 weeks</cell><cell>randomization d and every 6 weeks</cell></row><row><cell>progression</cell><cell>(± 7 days) until disease progression</cell><cell>(± 7 days) until disease progression</cell><cell>(± 7 days) until disease progression</cell></row><row><cell>(RECIST</cell><cell></cell><cell></cell><cell></cell></row><row><cell>v1.1) c</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Treatment</cell><cell>15.2 months (0.1-29.7)</cell><cell>16.9 months (0.03-28.7)</cell><cell>5.5 months (0.4-27.6) for the platinum-</cell></row><row><cell>exposure at</cell><cell></cell><cell></cell><cell>based doublet chemotherapy arm</cell></row><row><cell>data cut-off,</cell><cell></cell><cell></cell><cell>(control arm)</cell></row><row><cell>median</cell><cell></cell><cell></cell><cell></cell></row><row><cell>(range)</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">BICR blinded independent central review, DCR disease control rate, DoR duration of response, EGFR epidermal growth factor receptor, NC non-</cell></row><row><cell cols="4">calculable, ORR objective response rate, OS overall survival, PFS progression-free survival, RECIST response evaluation criteria in solid</cell></row><row><cell cols="2">tumours, TKI tyrosine kinase inhibitor, TL tumour lesion</cell><cell></cell><cell></cell></row><row><cell cols="4">a A subgroup of patients in the control arm with a confirmed T790M mutation has been used as a comparator with the AURA extension and</cell></row><row><cell cols="4">AURA2 patients; these patients received standard pemetrexed (500 mg/m 2 ) plus cisplastin (75 mg/m 2 ) chemotherapy (maximum six cycles,</cell></row><row><cell cols="2">intravenously on Day 1 of each cycle)</cell><cell></cell><cell></cell></row></table><note><p><s>b PFS and OS analyses were based on the 1 November 2016 data cut-off (DCO) from the AURA extension and AURA2 studies; ORR and DCR analyses were based on the 1 November 2015 DCO from the AURA extension and AURA2 studies c</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Baseline demographic and disease characteristics used for generation of the regression model for estimation of propensity scores Std diff standardised mean difference refers to the mean divided by the standard deviation used to measure effect size for selection of variables</s></p></div></figDesc><table><row><cell>Variable</cell></row></table><note><p><s>Smoking pack year history [0 = never, 1 = ever with pack years\30, 2 = ever with pack years C 30], n (%) a For categorical variables, p values were based on the Chi-square test or Fisher's exact test (50% or more of the cells have expected counts of less than 5).</s><s>For continuous variables, p values were based on the t test, or on the Wilcoxon rank-sum test if normality assumption was violated (Shapiro-Wilk test)</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc><div><p><s>Baseline demographics and disease characteristics for total patients and those patients receiving second-line treatment only with osimertinib or platinum-based doublet chemotherapy following cohort balancing</s></p></div></figDesc><table><row><cell>Variable</cell><cell cols="2">Total trimmed dataset</cell><cell cols="3">Trimmed dataset receiving second-line treatment</cell></row><row><cell></cell><cell></cell><cell></cell><cell>only</cell><cell></cell></row><row><cell></cell><cell>Osimertinib,</cell><cell>Platinum-based doublet</cell><cell>p value a Osimertinib,</cell><cell>Platinum-based doublet</cell><cell>p value a</cell></row><row><cell></cell><cell>n = 288</cell><cell>chemotherapy, n = 53</cell><cell>n = 92</cell><cell>chemotherapy, n = 53</cell></row><row><cell>Sex, n (%)</cell><cell></cell><cell></cell><cell>0.5341</cell><cell></cell><cell>0.7210</cell></row><row><cell>Male</cell><cell>96 (33.3)</cell><cell>30 (37.7)</cell><cell>32 (34.8)</cell><cell>20 (37.7)</cell></row><row><cell>Female</cell><cell>192 (66.7)</cell><cell>33 (62.3)</cell><cell>60 (65.2)</cell><cell>33 (62.3)</cell></row><row><cell>Age, years</cell><cell></cell><cell></cell><cell>0.0156</cell><cell></cell><cell>0.0082</cell></row><row><cell>Mean, SD</cell><cell>60.6 (10.7)</cell><cell>56.7 (10.3)</cell><cell>61.8 (11.3)</cell><cell>56.7 (10.3)</cell></row><row><cell>Median</cell><cell>60.5</cell><cell>56.0</cell><cell>60.0</cell><cell>56.0</cell></row><row><cell>Range</cell><cell>35.0-89.0</cell><cell>38.0-79.0</cell><cell>36.0-89.0</cell><cell>38.0-79.0</cell></row><row><cell>Region, n (%)</cell><cell></cell><cell></cell><cell>0.0018</cell><cell></cell><cell>\0.0001</cell></row><row><cell>Asia</cell><cell>175 (60.8)</cell><cell>40 (75.5)</cell><cell>48 (52.2)</cell><cell>40 (75.5)</cell></row><row><cell>Europe</cell><cell>48 (16.7)</cell><cell>13 (24.5)</cell><cell>14 (15.2)</cell><cell>13 (24.5)</cell></row><row><cell>North America</cell><cell>60 (20.8)</cell><cell>0 (0.0)</cell><cell>27 (29.3)</cell><cell>0 (0.0)</cell></row><row><cell>Rest of the world</cell><cell>5 (1.7)</cell><cell>0 (0.0)</cell><cell>3 (3.3)</cell><cell>0 (0.0)</cell></row><row><cell>Ethnicity, n (%)</cell><cell></cell><cell></cell><cell>0.4513</cell><cell></cell><cell>0.1380</cell></row><row><cell>Asian</cell><cell>193 (67.0)</cell><cell>40 (75.5)</cell><cell>55 (59.8)</cell><cell>40 (75.5)</cell></row><row><cell>Non-Asian</cell><cell>94 (32.6)</cell><cell>13 (24.5)</cell><cell>36 (39.1)</cell><cell>13 (24.5)</cell></row><row><cell>Not applicable</cell><cell>1 (0.3)</cell><cell>0 (0.0)</cell><cell>1 (1.1)</cell><cell>0 (0.0)</cell></row><row><cell>Time, from recent progression to</cell><cell></cell><cell></cell><cell>\0.0001</cell><cell></cell><cell>\0.0001</cell></row><row><cell>start of treatment, days</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean (SD)</cell><cell>74.1 (58.2)</cell><cell>16.9 (6.6)</cell><cell>75.7 (61.2)</cell><cell>16.9 (6.6)</cell></row><row><cell>Number of previous EGFR-TKIs,</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>including re-challenge, n (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head></head><label></label><figDesc><div><p><s>For categorical variables, p values were based on the Chi-square test or Fisher's exact test.</s><s>For categorical variables with more than two levels, an overall p value was calculated (instead of calculating p values for each level of the variable).</s></p></div></figDesc><table><row><cell cols="3">were analysed using a Cox proportional hazards model</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">with treatment as a factor and the estimated PS as a</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">covariate. Kaplan-Meier PFS and OS curves for osimer-</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">tinib and platinum-based doublet chemotherapy were</cell><cell></cell><cell></cell><cell></cell></row><row><cell>generated.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Differences in baseline variables were compared by</cell><cell></cell><cell></cell><cell></cell></row><row><cell>statistical tests.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Baseline target lesion size, mm</cell><cell></cell><cell></cell><cell>0.8882</cell><cell></cell><cell>0.6568</cell></row><row><cell>Mean (SD)</cell><cell>51.5 (28.1)</cell><cell>50.0 (23.0)</cell><cell>50.9 (28.6)</cell><cell>50.0 (23.0)</cell><cell></cell></row><row><cell>Site of disease at baseline, n (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Brain/central nervous system</cell><cell>99 (34.4)</cell><cell>17 (32.1)</cell><cell>0.7454 22 (23.9)</cell><cell>17 (32.1)</cell><cell>0.2858</cell></row><row><cell>Pleural effusion</cell><cell>105 (36.5)</cell><cell>20 (37.7)</cell><cell>0.8592 35 (38.0)</cell><cell>20 (37.7)</cell><cell>0.9707</cell></row><row><cell>Respiratory</cell><cell>174 (60.4)</cell><cell>19 (35.8)</cell><cell>0.0009 47 (51.1)</cell><cell>19 (35.8)</cell><cell>0.0760</cell></row><row><cell>Hepatic (including gall bladder)</cell><cell>62 (21.5)</cell><cell>10 (18.9)</cell><cell>0.6628 17 (18.5)</cell><cell>10 (18.9)</cell><cell>0.9537</cell></row><row><cell>Skin/soft tissue</cell><cell>12 (4.2)</cell><cell>2 (3.8)</cell><cell>0.8946 2 (2.2)</cell><cell>2 (3.8)</cell><cell>0.6233</cell></row><row><cell>Bone and locomotor</cell><cell>128 (44.4)</cell><cell>27 (50.9)</cell><cell>0.3825 38 (41.3)</cell><cell>27 (50.9)</cell><cell>0.2610</cell></row><row><cell>Lymph nodes</cell><cell>137 (47.6)</cell><cell>26 (49.1)</cell><cell>0.8421 40 (43.5)</cell><cell>26 (49.1)</cell><cell>0.5160</cell></row><row><cell>Pericardial effusion</cell><cell>13 (4.5)</cell><cell>4 (7.5)</cell><cell>0.3511 3 (3.3)</cell><cell>4 (7.5)</cell><cell>0.2591</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 3</head><label>3</label><figDesc><div><p><s>For categorical variables, p values were based on the Chi-square test or Fisher's exact test (50% or more of the cells have expected counts of less than 5).</s><s>For continuous variables, p values were based on t test, or on the Wilcoxon rank-sum test if normality assumption was violated (Shapiro-Wilk test)</s></p></div></figDesc><table><row><cell>continued</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Variable</cell><cell cols="2">Total trimmed dataset</cell><cell cols="3">Trimmed dataset receiving second-line treatment</cell></row><row><cell></cell><cell></cell><cell></cell><cell>only</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Osimertinib,</cell><cell>Platinum-based doublet</cell><cell>p value a Osimertinib,</cell><cell>Platinum-based doublet</cell><cell>p value a</cell></row><row><cell></cell><cell>n = 288</cell><cell>chemotherapy, n = 53</cell><cell>n = 92</cell><cell>chemotherapy, n = 53</cell><cell></cell></row><row><cell>Other</cell><cell>63 (21.9)</cell><cell>10 (18.9)</cell><cell>0.6238 18 (19.6)</cell><cell>10 (18.9)</cell><cell>0.9184</cell></row><row><cell cols="4">EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor, SD standard deviation</cell><cell></cell><cell></cell></row></table><note><p><s>a</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 4</head><label>4</label><figDesc><div><p><s>Summary of results of outcomes from indirect analysis and comparison with results from AURA3 randomized control trial Data for the OS analysis were not complete at the time of this report DCR disease control rate, HR hazard ratio, NC not calculable, OR odds ratio, ORR objective response rate, OS overall survival, PFS progressionfree survival Cox proportional hazards model with treatment as a factor and PS as a covariate.</s><s>HR\1 favours osimertinib.</s><s>Median stated for osimertinib versus chemotherapy the time of the data cut-off.</s><s>It should be noted that the AURA trials are both ongoing open-label studies; the OS data used in this analysis were from the most recent data cut-off (AURA extension and AURA2, 1 November 2016)</s></p></div></figDesc><table><row><cell></cell><cell>ORR a</cell><cell>DCR a</cell><cell>PFS b</cell><cell>OS b</cell></row><row><cell>Indirect</cell><cell>64.3 vs. 33.3%;</cell><cell>92.1 vs. 75.0%;</cell><cell>Median 10.9 vs. 5.3 months;</cell><cell>Median NC vs. 14.1 months;</cell></row><row><cell>comparison,</cell><cell>OR = 5.31, 95% CI</cell><cell>OR = 4.72, 95% CI</cell><cell>HR = 0.278, 95% CI</cell><cell>HR = 0.412, 95% CI</cell></row><row><cell>2L and C 3L</cell><cell>2.47-11.40, p\0.001</cell><cell>1.92-11.58, p\0.001</cell><cell>0.188-0.409, p\0.0001</cell><cell>0.273-0.622, p\0.0001</cell></row><row><cell>Indirect</cell><cell>67.4 vs. 33.3%;</cell><cell>93.3 vs. 75.0%;</cell><cell>Median 9.7 vs. 5.3 months;</cell><cell>Median 26.5 vs. 14.1 months;</cell></row><row><cell>comparison,</cell><cell>OR = 5.63, 95% CI</cell><cell>OR = 5.73, 95% CI</cell><cell>HR = 0.251, 95% CI</cell><cell>HR = 0.459, 95% CI</cell></row><row><cell>2L only</cell><cell>2.32-13.67, p\0.001</cell><cell>1.84-17.88, p = 0.003</cell><cell>0.155-0.405, p\0.0001</cell><cell>0.279-0.754, p = 0.0025)</cell></row><row><cell>AURA3 [24]</cell><cell>71 vs. 31%; OR = 5.39,</cell><cell>93% vs. 74%;</cell><cell>Median, 10.1 vs. 4.4 months;</cell><cell></cell></row><row><cell></cell><cell>95% CI 3.47-8.48,</cell><cell>OR = 4.76, 95% CI</cell><cell>HR = 0.30, 95% CI 0.23-0.41,</cell><cell></cell></row><row><cell></cell><cell>p\0.001</cell><cell>2.64-8.84, p\0.001</cell><cell>p\0.001</cell><cell></cell></row></table><note><p><s>aThe OR analysis was performed using logistic regression model with treatment as a factor and PS as a covariate.</s><s>OR[1 favours osimertinib.</s><s>% stated for osimertinib versus chemotherapy b Analysis of PFS was performed using a</s></p></note></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Conflict of interest HM and CB are employees of AstraZeneca.</s><s>FA worked as a consultant for AstraZeneca.</s><s>TM has participated in advisory roles for AstraZeneca and Eli Lilly and received honoraria from AstraZeneca and Eli Lilly.</s><s>TSKM is the Principal Investigator for the AURA3 trial (NCT02151981).</s><s>JC-HY has received honoraria for participating in advisory boards for Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Clovis Oncology, Eli Lilly, Merck Serono, Merck Sharp &amp; Dohme (MSD), Novartis, Ono Pharmaceutical, Pfizer, Roche/Genentech/Chugai and Yuhan.</s><s>CH is an employee of AstraZeneca and owns shares in AstraZeneca.</s></p><p><s>Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/),</s><s>which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Lord</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Inoue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1958" to="1965" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Mok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y-L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Thongprasert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Saijo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<biblScope unit="page" from="947" to="957" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">V</forename><surname>Sequist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>O'byrne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Hirsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mok</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="3327" to="3334" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFRmutant lung cancers</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Arcila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Rekhtman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Sima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Zakowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Pao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="2240" to="2247" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Balak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Riely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Somwar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Zakowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="6494" to="6501" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">EGFR mutation and resistance of non-smallcell lung cancer to gefitinib</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kobayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Boggon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Dayaram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Janne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Kocher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Meyerson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">352</biblScope>
			<biblScope unit="page" from="786" to="792" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kosaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yatabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Endoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tsuboi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="5764" to="5769" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">V</forename><surname>Sequist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Waltman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dias-Santagata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Digumarthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Turke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Fidias</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Transl Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="75" to="101" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, doubleblind Phase III trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>De Boer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O ´</forename><surname>Arrieta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C-H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gottfried</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Raats</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1067" to="1074" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Shepherd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Millward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Perrone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Seymour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1379" to="1388" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-smallcell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">V</forename><surname>Fossella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Devore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Kerr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Crawford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Natale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Dunphy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="2354" to="2362" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy</title>
		<author>
			<persName><forename type="first">N</forename><surname>Hanna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Shepherd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">V</forename><surname>Fossella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Pereira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Marinis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Pawel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1589" to="1597" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection</title>
		<author>
			<persName><forename type="first">A</forename><surname>Hata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Katakami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yoshioka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fujita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kunimasa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nanjo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="268" to="273" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Vandetanib plus docetaxel versus docetaxel as secondline treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Herbst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Eberhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Germonpre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Saijo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="619" to="626" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Y</forename><surname>Janjigian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Smit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Groen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Horn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gettinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Camidge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="1036" to="1045" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kawaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ando</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Asami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Okano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fukuda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nakagawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="1902" to="1908" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Shepherd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dancey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ramlau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mattson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gralla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>O'rourke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="2095" to="2103" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">N</forename><surname>Thatcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Parikh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Rodrigues</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ciuleanu</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)</title>
		<author>
			<persName><forename type="first">J</forename><surname>Pawel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">366</biblScope>
			<biblScope unit="page" from="1527" to="1537" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Janne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Planchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ohe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Ramalingam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page" from="1689" to="1699" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">EMA fast-tracks new oral treatment for non-small cell lung cancer</title>
		<ptr target="http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002448.jsp&amp;mid=WC0b01ac058004d5c1.Accessed21" />
	</analytic>
	<monogr>
		<title level="j">European Medicines Agency</title>
		<imprint>
			<date type="published" when="2017-09">Sept 2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Osimertinib: first global approval</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Greig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="263" to="273" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">LBA2_PR: osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results</title>
		<author>
			<persName><forename type="first">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Ramalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Janne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cantarini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mitsudomi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="S152" to="153" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title level="m" type="main">Tagrisso-met-primary-endpoint-in-phase-III-2nd-line-lung-cancer-trial-18072016</title>
		<author>
			<persName><surname>Astrazeneca</surname></persName>
		</author>
		<ptr target="https://www.astrazeneca.com/media-centre/press-releases/2016/" />
		<imprint>
			<date type="published" when="2017-09">Sept 2017</date>
		</imprint>
	</monogr>
	<note>Tagrisso met primary endpoint in phase III 2nd-line lung cancer trial</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Osimertinib or platinum-pemetrexed in EGFR T790-positive lung cancer</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Mok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Garassino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Ramalingam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">376</biblScope>
			<biblScope unit="page" from="629" to="640" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Soria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ahn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="990" to="998" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): final overall survival (OS) analysis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Soria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S-W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M-J</forename><surname>Ahn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>Abstr. 12010</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Introduction to propensity scores</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Forbes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Respirology</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="625" to="635" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution-a simulation study</title>
		<author>
			<persName><forename type="first">T</forename><surname>Sturmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Rothman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Avorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Glynn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="page" from="843" to="854" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Chemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Goldberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Oxnard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Digumarthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muzikansky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Jackman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">T</forename><surname>Lennes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1214" to="1220" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Gridelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ciardiello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gallo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Feld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Butts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Gebbia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="3002" to="3011" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maemondo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Inoue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kobayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sugawara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Oizumi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Isobe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="page" from="2380" to="2388" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Hirsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cadranel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="528" to="538" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Combined erlotinib and cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">M</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">B</forename><surname>Ren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cancer Res Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="2069" to="2077" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Re-Treatment with EGFR-TKIs in NSCLC patients who developed acquired resistance</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pers Med</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="297" to="310" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Efficacy and safety of erlotinib in the treatment for advanced non-small cell lung cancer in Chinese patients</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Liao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Zhou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Zhonghua Zhong Liu Za Zhi</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="148" to="151" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<monogr>
		<title/>
		<author>
			<persName><surname>Fda</surname></persName>
		</author>
		<author>
			<persName><surname>Osimertinib</surname></persName>
		</author>
		<ptr target="http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472565.htm.Accessed21" />
		<imprint>
			<date type="published" when="2017-09">Sept 2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title level="m" type="main">TM (osimertinib) approved in Japan for patients with EGFR T790M mutation-positive metastatic nonsmall cell lung cancer</title>
		<author>
			<persName><surname>Astrazeneca</surname></persName>
		</author>
		<author>
			<persName><surname>Tagrisso</surname></persName>
		</author>
		<ptr target="https://www.astrazeneca.com/media-centre/press-releases/2016/" />
		<imprint>
			<date type="published" when="2017-09-21">21 Sept 2017</date>
		</imprint>
	</monogr>
	<note>tagrisso-approved-in-japanfor-patients-with-egfr-t790m-mutation-positive-metastatic-nonsmall-cell-lung-cancer-29032016</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Oxnard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Thress</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Alden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lawrance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Paweletz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cantarini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="3375" to="3382" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Thress</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Brant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Carr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dearden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jenkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Brown</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="509" to="515" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
